There have been major changes in the top management of Sun Pharmaceutical Industries. The company has appointed Kirti Ganeorkar as the new managing director. He will replace Dilip Sanghvi from September 1, 2025, taking over this responsibility. The pharmaceutical company said in a statement that the entire business and all functions will work under the supervision of Ganeorkar. At the same time, Dilip Sanghvi will continue to preside over the company’s board as Executive Chairman.
The approval of the shareholders is yet to be taken in the upcoming annual general meeting of Sun Pharma on the appointment of Ganeorkar as MD. Ganeorkar has been leading India’s business in Sun Pharma since June 2019. Under his leadership, the company’s India business has steadily increased, which has further increased its market share. Earlier, Ganeorkar has played several leadership roles in the company in business development, marketing, merger and acquisitions, new product introduction, project management, IP and litigation.
He was associated with Sun Pharma in 1996
According to Sun Pharma, Ganeorkar has played an important role in entry in the company’s specialty sector by gaining the rights of innovative products like Ilumya. He led the company’s entry into Japan and prepared an initial base for entry in Europe. Ganeorkar, who holds Chemical Engineering and MBA degrees, joined Sun Pharma in 1996. He also supported American business with the operation of several major generic projects from concepts to commercialization. The company said that Sanghvi would focus on strengthening the company’s specialty portfolio.
Abhay Gandhi will leave the company
The statement further stated that North America’s President and CEO Abhay Gandhi has decided to carry forward his interests outside Sun Pharma. In the statement, Dilip Sanghvi said that Abhay has played an important role in furthering business development for Sun Pharma in geographical areas including US, India and emerging markets. Richard Escroft will replace Gandhi as the new CEO of North America.
Rick is an experienced bioframacutical executive who has more than three decades of experience in commercial operations, market access, medical matters and corporate matters in the US and global markets. Apart from this, the company’s hole time director and Chief Operating Officer Alok Sanghvi has also been entrusted with the responsibility of North America business, where Rick will report to Alok.
Shares have broken 10 percent so far this year
On June 13, Sun Pharma’s share on BSE remained flat to close at Rs 1688.70. The company’s market cap is Rs 4 lakh crore. The stock has come down 10 percent so far in the year 2025. The company had a 54.48 percent stake in the company till the end of March 2025.
